The Broad Institute of MIT and Harvard and Bayer announced the launch of the Precision Cardiology Laboratory (PCL), which will pursue scientific insights aimed at developing new therapies for heart failure.
The PCL’s initial goal is to develop high-resolution, single-cell maps of cardiovascular tissues in human and animal models. Using tissue samples donated by healthy individuals as well as people suffering from cardiovascular disease, researchers will build datasets to accelerate insights into heart failure.
Advertisement
The Broad-Bayer partnership began in 2013 with an oncology program. In 2015, the organizations launched a cardiovascular-specific collaboration aimed at using genomics to better understand cardiovascular disease. Now, the PCL will use non-genomic approaches to jumpstart the development of new therapeutics for heart failure.
